China's Alphamab Oncology falls third straight session to a year-low

Alphamab Oncology

15/11/2023 03:50

** Shares of China tumor immunobiology macromolecular
targeted drugs developer Alphamab Oncology  9966.HK  fall for
the third straight session to hit the lowest level in a year
    ** Stock plunges as much as 31.9% to HK$6.56, marking the
biggest one-day pct drop since debut in December 2019; stock is
biggest pct loser in Hang Seng Composite Index  .HSCI  
    ** Decline comes despite an independent report released by
the company late on Tuesday indentifying no additional safety
signal involving its pancreatic cancer drug candidate KN046-303
    ** Independent data monitoring committee recommended
continuing the study and to collect further follow-up overall
survival data till final analysis - co 
    ** Hang Seng Composite Index  .HSCI  rises 2.6%, healthcare
index  .HSCIH  adds 1.8%, Hang Seng Index  .HSI  surges 2.9%
    ** Stock down 33.7% YTD

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))